Enfusion, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENFN research report →
Price Chart
About the company
Enfusion, Inc. supplies cloud-based software solutions designed for the investment management sector, operating throughout the United States, Europe, the Middle East, Africa, and the Asia Pacific. Its product suite includes a sophisticated portfolio management system, which establishes an instant and comprehensive investment record.
- CEO
- Oleg Movchan
- IPO
- 2021
- Employees
- 1,143
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on ENFN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.02B
- P/E
- 572.34
- Fwd P/E
- 28.95
- PEG
- -9.74
- P/S
- 5.06
- P/B
- 13.53
- EV/EBITDA
- 160.18
- Div Yield
- 0.00%
- Gross Margin
- 67.82%
- Op Margin
- 3.05%
- Net Margin
- 1.40%
- ROE
- 4.45%
- ROIC
- 1.93%
Latest fiscal year · YoY change
- Revenue
- $201.61M+15.5%
- Gross Profit
- $136.74M+17.0%
- Op Income
- $6.16M
- Net Income
- $2.82M-53.1%
- EPS
- $0.02-81.2%
- OCF Growth
- +35.3%
- FCF Growth
- +94.5%
- 52W High
- $11.80
- 52W Low
- $7.83
- 50D MA
- $11.09
- 200D MA
- $9.90
- Beta
- 0.93
- RSI (14)
- 43
- Avg Volume
- 1.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Enfusion delivered 15% revenue growth in Q3 and continued to show up-market traction, while tightening full-year guidance on revenue and EBITDA.· November 4, 2024
- Q3 revenue was $51.2 million, up 15% year over year; adjusted EBITDA was $11.1 million with a 21.8% margin.
- ARR crossed $200 million for the first time, reaching $202.7 million, up 14% year over year and 4% sequentially.
- Bookings and client wins were strong, including 38 new clients, a total client count of 894, and several larger up-market wins tied to Portfolio Workbench.
- Management said new products and enhancements are expanding the serviceable market and supporting larger, more profitable relationships.
- Full-year 2024 guidance was tightened to $202 million-$205 million of revenue and $41 million-$45 million of EBITDA; free cash flow conversion guidance stays 50%-55%.
Q3 2024 revenue was $51.2 million, up 15% year over year. Adjusted EBITDA was $11.1 million, with adjusted EBITDA margin of 21.8%, up over 320 basis points from a year ago. Adjusted gross profit was $35.2 million, with adjusted gross margin of 68.8%, up 79 basis points year over year. GAAP net income was $2.0 million, or $0.02 per share; adjusted net income was $5.9 million, or $0.05 per share. ARR was $202.7 million, up 14% year over year and 4% from Q2; NDR was 102%. Adjusted free cash flow was $13.7 million, with 123% conversion in the quarter. The company ended the quarter with approximately $48 million in cash and cash equivalents and no debt. For 2024, Enfusion narrowed revenue guidance to $202 million-$205 million, EBITDA guidance to $41 million-$45 million, reiterated free cash flow conversion guidance of 50%-55%, and guided stock-based compensation to $19 million-$20 million.
Oleg Movchan framed the quarter as proof that Enfusion’s long-term strategy is starting to show up in the numbers, especially through product-led up-market expansion. He emphasized that Portfolio Workbench, managed services, and broader platform capabilities are helping the company win larger institutional clients that were previously out of reach. His tone was confident and strategic, with repeated focus on expanding the product shelf, geographic footprint, and institutional asset management presence.
Brad Herring highlighted the revenue mix as 14% from the front book and 1% from the back book, and said year-to-date bookings are running 16% ahead of last year. He pointed to adjusted gross margin of 68.8%, adjusted EBITDA margin of 21.8%, and adjusted free cash flow of $13.7 million, noting the quarter’s 123% conversion was driven by normal net working capital seasonality. He also said the company had about $48 million in cash, no debt, and $100 million of revolver capacity, and that year-end guidance was tightened because of strong new business offset by temporarily softer back-book growth.
Analysts focused on whether the business was being valued appropriately, the path to 2025 growth, and whether NDR and ARR weakness signaled a plateau. Management said they do not comment on rumors around strategic alternatives, and instead emphasized long-term value creation. On 2025, Brad said the company has more levers than it did entering 2024, including product rollout, pricing actions, and a broader up-market TAM, and he reiterated a view that margins can improve by a couple hundred basis points. On NDR, Brad said 102%-103% looks like a bottom, with churn and downgrades stabilizing and a roughly 60 basis point Q4 benefit as a prior customer impact rolls off.
The call showed clear traction in up-market client wins, with management repeatedly citing Workbench, managed services, and broader product breadth as reasons the company can win larger accounts. Revenue grew 15%, ARR crossed $200 million, and management said bookings, average deal sizes, and geographic expansion all support confidence in 2025 and beyond.
Back-book growth was muted, especially in Asia and among domestic hedge fund clients, and management acknowledged client scrutiny on OpEx ahead of the election. NDR was only 102%, down sequentially, and ARR can still look choppy because monetization lags bookings, so near-term metrics may not fully reflect recent wins.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 48.9%
- Shares Outstanding
- 94.80M
- Float Shares
- 46.32M
of shares held by institutions
137 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 3.08M | ▲ 506.82K |
| Nuveen Asset Management, LLC | 95.82K | 0 |
| Relative Value Partners Group, LLC | 25.00K | ▲ 25.00K |
| Lindbrook Capital, LLC | 76 | ▲ 76 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 25 | ICONIQ Strategic Partners V, L.P. | other | 7,748,000 |
| Apr 21, 25 | ICONIQ Strategic Partners V, L.P. | other | 5,030,000 |
| Apr 21, 25 | Luo Roy | sell | 7,748,000 |
| Apr 21, 25 | Luo Roy | sell | 5,030,000 |
| Apr 21, 25 | Pawar Neal | sell | 135,613 |
| Apr 21, 25 | Pawar Neal | sell | 501,695 |
| Apr 21, 25 | Pawar Neal | sell | 580,000 |
| Apr 21, 25 | Herring Bradley | sell | 108,332 |
| Apr 21, 25 | Herring Bradley | sell | 216,357 |
| Apr 21, 25 | Movchan Oleg | sell | 51,808 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENFN coverage
Recent articles, reports, and earnings notes.
No research on ENFN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENFN report →Clearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful Growth
seekingalpha.com · Nov 12
Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy
seekingalpha.com · Apr 24
Clearwater Analytics Finalizes Acquisition of Enfusion
businesswire.com · Apr 21
Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration
businesswire.com · Apr 17
Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration
businesswire.com · Apr 2
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN
businesswire.com · Apr 2
Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates
zacks.com · Mar 3
Enfusion Announces Fourth Quarter and Full Year 2024 Results
businesswire.com · Mar 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.